Patents by Inventor Andrew D. J. Goodearl

Andrew D. J. Goodearl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120045777
    Abstract: The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods using compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.
    Type: Application
    Filed: June 27, 2011
    Publication date: February 23, 2012
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher C. Fraser, Thomas M. Barnes, John D. Sharp, Susan J. Kirst, Paul S. Myers, Kevin R. Leiby, Douglas A. Holtzman, Sean A. McCarthy, Nicholas Wrighton, Charles R. Mackay, Andrew D.J. Goodearl
  • Publication number: 20110171205
    Abstract: The invention provides isolated nucleic acids molecules, designated 15571, 2465, 14266, 2882, 52871, 8203 or 16852 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 15571, 2465, 14266, 2882, 52871, 8203 or 16852 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 15571, 2465, 14266, 2882, 52871, 8203 or 16852 gene has been introduced or disrupted. The invention still further provides isolated 15571, 2465, 14266, 2882, 52871, 8203 or 16852 proteins, fusion proteins, antigenic peptides and anti-15571, 2465, 14266, 2882, 52871, 8203 or 16852 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: January 25, 2011
    Publication date: July 14, 2011
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Martin R. Hodge, Clare M. Lloyd, Nadine S. Weich, Jose M. Lora, David White, Maria A. Glucksmann, Keith E. Robison, Inmaculada Silos-Santiago, Andrew D.J. Goodearl, Rory A.J. Curtis
  • Publication number: 20100062487
    Abstract: The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods using compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.
    Type: Application
    Filed: May 8, 2009
    Publication date: March 11, 2010
    Inventors: Christopher C. Fraser, Thomas M. Barnes, John D. Sharp, Susan J. Kirst, Paul S. Myers, Kevin R. Leiby, Douglas A. Holtzman, Sean A. McCarthy, Nicholas Wrighton, Charles R. Mackay, Andrew D.J. Goodearl
  • Publication number: 20090226450
    Abstract: The invention provides isolated nucleic acids molecules, designated 15571, 2465, 14266, 2882, 52871, 8203 or 16852 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 15571, 2465, 14266, 2882, 52871, 8203 or 16852 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 15571, 2465, 14266, 2882, 52871, 8203 or 16852 gene has been introduced or disrupted. The invention still further provides isolated 15571, 2465, 14266, 2882, 52871, 8203 or 16852 proteins, fusion proteins, antigenic peptides and anti-15571, 2465, 14266, 2882, 52871, 8203 or 16852 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: April 23, 2009
    Publication date: September 10, 2009
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Martin R. Hodge, Clare M. Lloyd, Nadine S. Weich, Jose M. Lora, David White, Maria A. Glucksmann, Keith E. Robison, Inmaculada Silos-Santiago, Andrew D.J. Goodearl, Rory A.J. Curtis
  • Publication number: 20090136959
    Abstract: The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods using compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.
    Type: Application
    Filed: October 23, 2008
    Publication date: May 28, 2009
    Inventors: Sean A. McCarthy, Christopher C. Fraser, John D. Sharp, Thomas M. Barnes, Susan J. Kirst, Paul S. Myers, Nicholas Wrighton, Andrew D.J. Goodearl, Douglas A. Holtzman, Mehran Khodadoust
  • Publication number: 20040253605
    Abstract: The invention relates to Tango-71, Tango-79, and Tango-81 polypeptides, nucleic acid molecules encoding Tango-71, Tango-79, and Tango-81, and uses thereof. The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods using compositions of the invention are also provided.
    Type: Application
    Filed: November 20, 2003
    Publication date: December 16, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Sean A. McCarthy, Douglas A. Holtzman, Andrew D.J. Goodearl
  • Publication number: 20040121396
    Abstract: The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods using compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.
    Type: Application
    Filed: December 19, 2003
    Publication date: June 24, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher C. Fraser, Thomas M. Barnes, John D. Sharp, Susan J. Kirst, Paul S. Myers, Kevin R. Leiby, Douglas A. Holtzman, Sean A. McCarthy, Nicholas Wrighton, Charles R. MacKay, Andrew D.J. Goodearl
  • Publication number: 20030170621
    Abstract: The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods using compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.
    Type: Application
    Filed: January 19, 2001
    Publication date: September 11, 2003
    Inventors: Sean A. McCarthy, Christopher C. Fraser, John D. Sharp, Thomas M. Barnes, Susan J. Kirst, Paul S. Myers, Nicholas Wrighton, Andrew D.J. Goodearl, Douglas A. Holtzman, Mehran Khodadoust
  • Publication number: 20030159162
    Abstract: The invention relates to OCT-3 polypeptides, nucleic acid molecules encoding OCT-3, and uses thereof. OCT-3 is a protein that is expressed in the plasma membrane of biological cells, across which it regulates the transport of organic molecules.
    Type: Application
    Filed: March 11, 2003
    Publication date: August 21, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Andrew D. J. Goodearl, Inmaculada Silos-Santiago
  • Publication number: 20030143632
    Abstract: The invention relates to Tango-73, Tango-74, Tango-76, Tango-78, and Tango-83 polypeptides, nucleic acid molecules encoding Tango-73, Tango-74, Tango-76, Tango-78, and Tango-83, and uses thereof. The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods using compositions of the invention are also provided.
    Type: Application
    Filed: February 12, 2003
    Publication date: July 31, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Douglas A. Holtzman, Andrew D.J. Goodearl, Sean A. McCarthy
  • Publication number: 20030110519
    Abstract: The invention provides isolated nucleic acids molecules, designated muscarinic acetylcholine receptor 6 (“mACHR-6”) nucleic acid molecules, which encode polypeptides involved in the modulation of acetylcholine responses in acetylcholine responsive cells. The invention also provides antisense nucleic acid molecules, expression vectors containing mACHR-6 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which an mACHR-6 gene has been introduced or disrupted. The invention still further provides isolated mACHR-6 polypeptides, fusion polypeptides, antigenic peptides, and anti-mACHR-6 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: October 28, 2002
    Publication date: June 12, 2003
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Andrew D.J. Goodearl, M. Alexandra Glucksmann
  • Publication number: 20030104447
    Abstract: The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods using compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.
    Type: Application
    Filed: October 11, 2002
    Publication date: June 5, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Douglas A. Holtzman, Andrew D.J. Goodearl, Sean A. McCarthy
  • Patent number: 6573057
    Abstract: The invention relates to OCT-3 polypeptides, nucleic acid molecules encoding OCT-3, and uses thereof. OCT-3 is a protein that is expressed in the plasma membrane of biological cells, across which it regulates the transport of organic molecules.
    Type: Grant
    Filed: November 2, 2001
    Date of Patent: June 3, 2003
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Andrew D. J. Goodearl, Inmaculada Silos-Santiago
  • Publication number: 20030022279
    Abstract: The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods using compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.
    Type: Application
    Filed: January 12, 2001
    Publication date: January 30, 2003
    Inventors: Christopher C. Fraser, Thomas M. Barnes, John D. Sharp, Susan J. Kirst, Paul S. Myers, Kevin R. Leiby, Douglas A. Holtzman, Sean A. McCarthy, Nicholas Wrighton, Charles R. MacKay, Andrew D.J. Goodearl
  • Publication number: 20020168708
    Abstract: The invention provides isolated nucleic acids molecules, designated muscarinic acetylcholine receptor 6 (“mACHR-6”) nucleic acid molecules, which encode polypeptides involved in the modulation of acetylcholine responses in acetylcholine responsive cells. The invention also provides antisense nucleic acid molecules, expression vectors containing mACHR-6 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which an mACHR-6 gene has been introduced or disrupted. The invention still further provides isolated mACHR-6 polypeptides, fusion polypeptides, antigenic peptides, and anti-mACHR-6 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: October 5, 1998
    Publication date: November 14, 2002
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: ANDREW D.J. GOODEARL, ALEXANDRA GLUCKSMANN
  • Publication number: 20020166131
    Abstract: The invention provides isolated nucleic acids molecules, designated muscarinic acetylcholine receptor 6 (“mACHR-6”) nucleic acid molecules, which encode polypeptides involved in the modulation of acetylcholine responses in acetylcholine responsive cells. The invention also provides antisense nucleic acid molecules, expression vectors containing mACHR-6 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which an mACHR-6 gene has been introduced or disrupted. The invention still further provides isolated mACHR-6 polypeptides, fusion polypeptides, antigenic peptides, and anti-mACHR-6 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: July 8, 1999
    Publication date: November 7, 2002
    Applicant: Millennium Pharmaceuticals, Inc
    Inventors: ANDREW D. J. GOODEARL, M. ALEXANDRA GLUCKSMANN
  • Publication number: 20020160386
    Abstract: The invention relates to OCT-3 polypeptides, nucleic acid molecules encoding OCT-3, and uses thereof. OCT-3 is a protein that is expressed in the plasma membrane of biological cells, across which it regulates the transport of organic molecules.
    Type: Application
    Filed: November 2, 2001
    Publication date: October 31, 2002
    Applicant: Millennium Pharmaceuticals, Inc., a Delaware corporation
    Inventors: Andrew D.J. Goodearl, Inmaculada Silos-Santiago
  • Publication number: 20020137142
    Abstract: The invention relates to Tango-71, Tango-73, Tango-74, Tango-76, and Tango-83, polypeptides, nucleic acid molecules encoding Tango-71, Tango-73, Tango-74, Tango-76, and Tango-83, and uses thereof.
    Type: Application
    Filed: March 25, 2002
    Publication date: September 26, 2002
    Applicant: Millennium Pharmaceuticals, Inc., a Delaware corporation
    Inventors: Douglas A. Holtzman, Andrew D.J. Goodearl
  • Publication number: 20020112251
    Abstract: The invention relates to Tango-71, Tango-79, and Tango-81 polypeptides, nucleic acid molecules encoding Tango-71, Tango-79, and Tango-81, and uses thereof. The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods using compositions of the invention are also provided.
    Type: Application
    Filed: March 9, 2001
    Publication date: August 15, 2002
    Inventors: Sean A. McCarthy, Douglas A. Holtzman, Andrew D.J. Goodearl
  • Publication number: 20020099199
    Abstract: The invention provides isolated nucleic acids molecules, designated muscarinic acetylcholine receptor 6 (“mACHR-6”) nucleic acid molecules, which encode polypeptides involved in the modulation of acetylcholine responses in acetylcholine responsive cells. The invention also provides antisense nucleic acid molecules, expression vectors containing mACHR-6 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which an mACHR-6 gene has been introduced or disrupted. The invention still further provides isolated mACHR-6 polypeptides, fusion polypeptides, antigenic peptides, and anti-mACHR-6 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: July 8, 1999
    Publication date: July 25, 2002
    Inventors: ANDREW D.J. GOODEARL, M. ALEXANDRA GLUCKSMANN